Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival

Annals of the New York Academy of Sciences

Volumn 1138, Issue , 2008, Pages 393-403

  Choi, Jang Hyun ^a   Yang, Yong Ryoul ^a   Lee, Seul Ki ^a   Kim, Sun Hee ^a   Kim, Yun Hee ^a   Cha, Joo Young ^b   Oh, Se Woong ^b   Ha, Jong Ryul ^b   Ryu, Sung Ho ^a   Suh, Pann Ghill ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Choongwae Pharma Co   (South Korea)

Author keywords

Akt; Apoptosis; Cancer cells; PDK1; Phenothiazines; Proliferation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CHLORPROMAZINE; DIMETHYL SULFOXIDE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; ETOPOSIDE; FLUPHENAZINE; HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; PACLITAXEL; PHENOTHIAZINE DERIVATIVE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; SIGNAL TRANSDUCTION; TUMOR GROWTH;

MUS MUSCULUS;

EID: 53149140694     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1414.041     Document Type: Conference Paper

References (28)

1. Vivanco, I. & C.L. Sawyers. 2002. The phosphoinositol 3-kinase Akt pathway in human cancer. Nat. Rev. Can. 2 : 489 501.
2. Fruman, D.A., R.E. Meyers & L.C. Cantley. 1998. Phosphoinositide kinases. Annu. Rev. Biochem. 67 : 481 507.
3. Toker, A. & A.C. Newton. 2000. Cellular signaling: pivoting around PDK1. Cell 103 : 185 188.
4. Downward, J. 1998. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10 : 262 267.
5. Franke, T.F. et al. 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275 : 665 668.
6. Harada, H. et al. 2001. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. USA 98 : 9666 9670.
7. Cross, D.A. et al. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 : 785 789.
8. Datta, S.R. et al. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 : 231 241.
9. Biggs, W.H. III. et al. 1999. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. USA 96 : 7421 7426.
10. Staal, S.P. 1987. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA 84 : 5034 5037.
11. Datta, S.R., A. Brunet & M.E. Greenberg. 1999. Cellular survival: a play in three Akts. Genes Dev. 13 : 2905 2927.
12. Sun, M. et al. 2001. AKT1/PKB kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 159 : 431 437.
13. Holland, E.C. et al. 2000. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25 : 55 57.
14. Malstrom, S. et al. 2001. Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc. Natl. Acad. Sci. USA 98 : 14967 14972.
15. Baldessarini, R.J. & F.I. Tarazi. 2001. Drugs and the treatment of psychiatric disorders. In The Pharmacological Basis of Therapeutics. J.G. Hardman & L.E. Limbird, Eds. : 971 1002. McGraw Hill. New York, NY.
16. Lopez-Girona, A. et al. 1992. Calmodulin regulates DNA polymerase a activity during proliferative activation of NRK cells. Biochem. Biophys. Res. Commun. 184 : 1517 1523.
17. Komoda, T. et al. 1985. Inhibitory effect of phenothiazine derivatives on bone in vivo and osteoblastic cells in vitro. Biochem. Pharmacol. 34 : 3885 3889.
18. Schleuning, M., V. Brumme & W. Wilmanns. 1993. Growth inhibition of human leukemic cell lines by the phenothiazine derivative fluphenazine. Anticancer Res. 13 : 599 602.
19. Glass-Marmor, L., H. Morgenstern & R. Beitner. 1996. Calmodulin antagonists decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability of melanoma cells. Eur. J. Pharmacol. 313 : 265 271.
20. Zhu, H.G. et al. 1991. Different susceptibility of lung cell lines to inhibitors of tumor promotion and inducers of differentiation. J. Biol. Regul. Homeost. Agents 5 : 52 58.
21. Choi, J.H. et al. 2006. Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B. Nat. Cell Biol. 8 : 1389 1397.
22. Hamilton, T.C. et al. 1984. Induction of progesterone receptor with 17beta-estradiol in human ovarian cancer. J. Clin. Endocrinol. Metab. 59 : 561 563.
23. Levin, R.M. & B. Weiss. 1977. Binding of trifluoperazine to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. Mol. Pharmacol. 13 : 690 697.
24. Egea, J. et al. 2001. Neuronal survival induced by neurotrophins requires calmodulin. J. Cell Biol. 154 : 585 597.
25. Kau, T.R. et al. 2003. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 4 : 463 476.
26. Yang, C. et al. 2000. Calmodulin antagonists inhibit insulin-stimulated GLUT4 (glucose transporter 4) translocation by preventing the formation of phosphatidylinositol 3,4,5-trisphosphate in 3T3L1 adipocytes. Mol. Endocrinol. 14 : 317 326.
27. Graves, L.M. et al. 1997. An intracellular calcium signal activates p70 but not p90 ribosomal S6 kinase in liver epithelial cells. J. Biol. Chem. 272 : 1920 1928.
28. Ashburn, T.T. & K.B. Thor. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Disc. 3 : 673 683.